| Title: |
An international observational study validating gene-expression sepsis immune subgroups |
| Authors: |
B. Antcliffe, David; Peronnet, Estelle; Pène, Frédéric; Strålin, Kristoffer; Brealey, David; Blein, Sophie; Cleaver, Richard; Cronhjort, Maria; Diehl, Jean-Luc; Voiriot, Guillaume; Fleurie, Aurore; Lannsjö, Claudia; Lukaszewicz, Anne-Claire; Mårtensson, Johan; Pham, Tài; de Prost, Nicolas; Ricard, Jean-Damien; Singer, Mervyn; Terraz, Gabriel; Timsit, Jean-François; Unge, Christian; Vieillard-Baron, Antoine; Rubenson Wahlin, Rebecka; Llitjos, Jean-François; C. Gordon, Anthony |
| Contributors: |
Imperial College London; Université Claude Bernard Lyon 1 (UCBL); Université de Lyon; BIOMERIEUX Lyon, France; Hospices Civils de Lyon (HCL); Université Paris 13 (UP13); Institut National de la Santé et de la Recherche Médicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Hôpital Cochin AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Institut Cochin (IC UM3 (UMR 8104 / U1016)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité); Karolinska University Hospital Stockholm; Hôpital Européen Georges Pompidou APHP (HEGP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO); Centre de Recherche Saint-Antoine (CRSA); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU); Karolinska Institutet = Karolinska Institute Stockholm; Université Paris-Saclay; Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse; AP-HP. Université Paris Saclay-AP-HP. Université Paris Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Hôpital Louis Mourier - AP-HP Colombes; Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord; University College London Hospitals (UCLH); Université Sorbonne Paris Cité (USPC); AP-HP - Hôpital Bichat - Claude Bernard Paris |
| Source: |
ISSN: 1364-8535. |
| Publisher Information: |
CCSD; BioMed Central |
| Publication Year: |
2025 |
| Collection: |
Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| Subject Terms: |
Sepsis; Gene-expression; Transcriptomics; Prospective study; [SDV]Life Sciences [q-bio] |
| Description: |
International audience ; Background Sepsis gene-expression sub-phenotypes with prognostic and theranostic potential have been discovered. These have been identified retrospectively and have not been translated to methods that could be deployed at the bedside. We aimed to identify subgroups of septic patients at high-risk of poor outcome, using a rapid, multiplex RNA-based test. Methods Adults with sepsis, in the intensive care unit (ICU) were recruited from 17 sites in the United Kingdom, Sweden and France. Blood was collected at days 2–5 (S1), 6–8 (S2) and 13–15 (S3) after ICU admission and analyzed centrally. Patients were assigned into ‘high' and ‘low' risk groups using two models previously developed for the Immune-Profiling Panel prototype on the bioMérieux FilmArray® system. Results 357 patients were recruited (March 2021–November 2022). 69% were male with a median age of 67 years, APACHE II score of 21 and a 30% 90-day mortality rate. The proportions of high-risk patients decreased over the three sampling times (model 1: 53%, 40%, 15% and model 2: 81%, 74%, 37%). In model 1, 90-day mortality was higher in a high-risk group at each time (S1: 35% vs 24%, p = 0.04; S2: 43% vs 20%, p < 0.001; S3: 52% vs 24%, p = 0.007). In model 2, mortality was only significantly different at the second sampling time (S1: 30% vs 27%, p = 0.77; S2: 34% vs 14%, p = 0.002; S3: 35% vs 23%, p = 0.13). Conclusions Gene-expression diagnostics can identify patients with sepsis at high-risk of poor outcomes and could be used to identify patients for precision medicine trials. Registration ISRCTN11364482 Registered 24th September 2020. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40033354; PUBMED: 40033354 |
| DOI: |
10.1186/s13054-025-05319-5 |
| Availability: |
https://hal.science/hal-04980703; https://hal.science/hal-04980703v1/document; https://hal.science/hal-04980703v1/file/s13054-025-05319-5.pdf; https://doi.org/10.1186/s13054-025-05319-5 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.AF1E57AD |
| Database: |
BASE |